NASDAQ:BIIB

Biogen Stock Insider Trading

Healthcare > Drug Manufacturers - General

Buy BIIB

*Your capital is at risk

$197.19

-2.52 (-1.26%)

At Close: Jun 23, 2026

Biogen Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 67.69. In total, the insiders bought 274.46K and sold 30.57K BIIB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	67.69
● Buy	274.46K shares
● Sell	30.57K shares
73% Buy Activity Weak Negative Correlation
Buy Signal Medium Confidence Feb 13, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 67.69. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 09, 2026 Buy	Common Stock M-Exempt	Pangalos Menelas N Director	Director	2 370 Value: $471.9K
Jun 09, 2026 Buy	Common Stock A-Award	Minor Lloyd Director	Director	1 505 Value: $299.6K
Jun 09, 2026 Buy	Common Stock A-Award	Freire Maria C Director	Director	2 005 Value: $399.2K
Jun 09, 2026 Buy	Common Stock A-Award	Hawkins William A Director	Director	1 505 Value: $299.6K
Jun 09, 2026 Buy	Common Stock A-Award	Langer Susan Director	Director	1 505 Value: $299.6K
Jun 09, 2026 Buy	Common Stock A-Award	Mantas Jesus B Director	Director	1 505 Value: $299.6K
Jun 09, 2026 Buy	Common Stock A-Award	Rowinsky Eric K Director	Director	1 505 Value: $299.6K
Jun 09, 2026 Buy	Common Stock A-Award	Sherwin Stephen A Director	Director	1 505 Value: $299.6K
Jun 09, 2026 Buy	Restricted Stock Unit M-Exempt	Pangalos Menelas N Director	Director	2 370 Value: $471.9K
Jun 09, 2026 Buy	Common Stock A-Award	Pangalos Menelas N Director	Director	1 505 Value: $299.6K
Jun 09, 2026 Buy	Common Stock A-Award	Patolawala Monish D Director	Director	1 505 Value: $299.6K
May 01, 2026 Buy	Restricted Stock Unit M-Exempt	Keeney Adam Head Of Corporate Development	Officer	939 Value: $175.6K
May 01, 2026 Buy	Common Stock M-Exempt	Keeney Adam Head Of Corporate Development	Officer	939 Value: $175.6K
May 01, 2026 Sell	Common Stock F-InKind	Keeney Adam Head Of Corporate Development	Officer	455 Value: $85.1K
Apr 01, 2026 Buy	Common Stock M-Exempt	Godbout Sean Chief Accounting Officer	Officer	181 Value: $33.3K
Apr 01, 2026 Sell	Common Stock F-InKind	Godbout Sean Chief Accounting Officer	Officer	54 Value: $10K
Apr 01, 2026 Buy	Restricted Stock Unit M-Exempt	Godbout Sean Chief Accounting Officer	Officer	181 Value: $33.3K
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Alexander Susan H EVP Chief Legal Officer	Officer	8 450 Value: $1.66M
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Godbout Sean Chief Accounting Officer	Officer	1 800 Value: $353.7K
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Keeney Adam Head Of Corporate Development	Officer	8 025 Value: $1.58M
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Kramer Robin Chief Financial Officer	C-Suite Officer	8 450 Value: $1.66M
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Murphy Nicole Head Of Pharm Ops And Tech	Officer	10 560 Value: $2.08M
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Viehbacher Christopher President And CEO	CEO / President	38 015 Value: $7.47M
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Singhal Priya Head Of Development	Officer	10 560 Value: $2.08M
Feb 13, 2026 Buy	Restricted Stock Unit A-Award	Izzar Rachid Head Of Global Product Strat.	Officer	7 390 Value: $1.45M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOGEN INC.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...

Read Full Profile Here